BPC-157 (Oral) vs LL-37
A side-by-side research comparison of BPC-157 (Oral) and LL-37 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BPC-157 (Oral) | LL-37 |
|---|---|---|
| Full name | BPC-157 Oral Formulation (Arginate Salt) | Cathelicidin Antimicrobial Peptide LL-37 |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | Research compound |
| Mechanism | Same mechanism as injectable BPC-157 but delivered orally. Upregulates VEGF, modulates NO system, and promotes gut mucosal healing through direct contact and systemic absorption. | Disrupts microbial membranes, neutralizes endotoxins, recruits immune cells via chemotaxis, and promotes angiogenesis and re-epithelialization. |
| Molecular weight | 1419.53 Da | 4493.33 Da |
| Half-life | ~4 hours (oral bioavailability lower but sustained) | ~4-6 hours |
| Bioavailability | ~40-60% oral (arginate salt form) | Variable by route; topical and injectable |
| Typical dose | 500 mcg - 1 mg | 50-100 mcg |
| Frequency | 1-2x daily | Daily |
| Route | Oral capsule (arginate salt) | Topical or subcutaneous injection |
BPC-157 (Oral) reported benefits
- Gut healing (direct contact)
- Liver protection
- Oral convenience
- Systemic anti-inflammatory
- No injection required
LL-37 reported benefits
- Broad-spectrum antimicrobial
- Wound healing acceleration
- Biofilm disruption
- Immune system enhancement
Related comparisons
Research and educational reference only. Not medical advice.